Abstract: A method for preparation pharmaceutical compounds in large quantities consists of copper (I) halide, preferably the chloride complex of nicotinic acid characterized by elemental analysis, spectroscopy and crystallographic methods, used for treatment of muscular dystrophy, myopathy, myasthenia gravis, parkinsonism, Chronic Fatigue Syndrome, Male Infertility and post stroke muscle weakness. Chlorobis (nicotinic acid) copper (I) monohydrate complex, its composition [CuCl(nicotinic acid)2]. H2O, has been prepared and its physical and chemical properties as well as its crystal structure have been investigated for the first time.

Abstract: The invention relates to an avocado extract rich in polyphenols, containing at least 10% by weight of polyphenols, expressed in gallic acid equivalent relative to the dry extract obtained, wherein said polyphenols contain procyanidins, cafeic acid and cafeic acid derivatives, typically in a proportion of at least 70% by weight, expressed in gallic acid equivalent relative to the total polyphenol content by weight. The invention also relates to a composition comprising an extract according to the invention as active agent and a suitable excipient. The invention also relates to such a composition or such an extract for use thereof in preventing or treating disorders or pathological conditions of the skin, the mucous membranes or the superficial body growths.

Abstract: The present invention relates to ruthenium complexes, and in particular di- and multi-nuclear ruthenium complexes which may be used as antimicrobial agents. The invention also relates to pharmaceutical compositions comprising such complexes, and methods for their use in treating or preventing microbial infections.

Abstract: The invention relates to an anti-dandruff shampoo comprising: a) from 0.1 to 5 wt. % of an anti-dandruff zinc salt; b) from 2 to 16 wt. % of an alkyl sulphate and/or an ethoxylated alkyl sulfate anionic surfactant; and, c) from 1 to 10 wt. % of a fatty acyl isethionate product which product comprises 40 to 80 wt. % fatty acyl isethionate and 15 to 50 wt. % free fatty acid and/or fatty acid salt and to the use of the fatty acyl isethionate product to provide a conditioning benefit to hair treated with an anti-dandruff shampoo comprising anti-dandruff zinc salts.

Abstract: The invention relates to an anti-dandruff shampoo comprising:—a) from 0.1 to 5 wt. % of an anti-dandruff zinc salt; b) from 1 to 8 wt. % of an alkyl glycinate and/or alkyl carboxyglycinate; c) from 2 to 16 wt. % of an alkyl sulphate and/or an ethoxylated alkyl sulfate anionic surfactant; and, d) from 1 to 10 wt. % of a fatty acyl isethionate product which product comprises 40 to 80 wt. % fatty acyl isethionate and 15 to 50 wt. % free fatty acid and/or fatty acid salt and to the use of a surfactant system comprising components b) to d) to provide an improvement to the skin stratum corneum barrier.

Abstract: The present invention provides organic arsenicals which may be used to treat numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.

Abstract: The invention provides methods of treating cancer, especially breast cancer, and in particular HER2/ErbB2 positive breast cancer using a FoxM1 inhibitor in conjunction with trastuzumab and/or paclitaxel. Pharmaceutical compositions comprising a FoxM1 inhibitor in the presence of trastuzumab and/or paclitaxel are also provided. The invention further provides methods of identifying and treating trastuzumab resistant and/or paclitaxel resistant cancer. Also provided are methods of promoting breast tumor cell differentiation.

Abstract: The present invention is directed to methods of using combination therapies containing [2-({4-[(dimethylamino)iminomethyl]phenyl}carbonylamino)-5-methoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide for the treatment of thrombotic disease(s) and pharmaceutical compositions thereof.

Abstract: The invention provides supramolecular metal complexes as DNA cleaving agents. In the complexes, charge is transferred from one light absorbing metal (e.g. Ru or Os) to an electron accepting metal (e.g. Rh) via a bridging ?-acceptor ligand. A bioactive metal-to-metal charge transfer state capable of cleaving DNA is thus generated. The complexes function when irradiated with low energy visible light with or without molecular oxygen.

Abstract: The invention relates to a cosmetic composition comprising, in a cosmetically acceptable medium: (i) one or more compounds selected from ellagic acid, its ethers and the salts of ellagic acid and its ethers, and (ii) one or more compounds selected from pyrithione salts, 1-hydroxy-2-pyridone derivatives and selenium (poly)sulphides, in a weight ratio of the amount of active(s) (i) to the amount of antidandruff agent(s) (ii) of greater than or equal to 0.5. The invention also relates to a method of cosmetic treatment employing such a composition, and to the use of this composition for the treatment of dandruff conditions and for reducing the phenomena of irritation and itching.

Abstract: The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias.

Abstract: The present invention is directed to a personal care composition comprising an effective amount of a pyrithione or a polyvalent metal salt of a pyrithione; an effective amount of an iron chelator or a material which chelates iron; wherein the combination of the iron chelator and the pyrithione or a polyvalent metal salt of a pyrithione has a fractional inhibitor concentration of less than or equal to 1.

Abstract: The present invention relates to a biocidal coating composition comprising a biocide and an organofunctional silane oligomer which is distinct from the biocide. Such compositions are suitable for application to a substrate surface to provide long term disinfection on the surface of the substrate. The organofunctional silane oligomer prolongs the action of the biocide on the surface of the substrate, and provides improved surface-retention of the biocide.

Abstract: The present invention provides a therapeutic agent for hyperlipidemia having an excellent effect of lowering the cholesterol and triglyceride level in blood plasma. The present invention relates to a prophylactic and/or therapeutic agent for hyperlipidemia, a prophylactic and/or therapeutic agent for obesity or diabetes mellitus, and a prophylactic and/or therapeutic agent for metabolic syndrome, each agent including a compound represented by the formula (1), or a salt thereof, and a statin, particularly pitavastatin, in combination.

Abstract: Silver(I) cyanoximates of AgL composition (L=NC—C(NO)—R, where R is electron withdrawing groups: —CN, —C(O)NR2, —C(O)R? (alkyl), —C(O)OEt, 2-heteroaryl fragments such as 2-pyridyl, 2-benzimidazolyl, 2-benzoxazolyl, 2-benzthiazolyl) are synthesized and characterized using spectroscopic methods and X-ray analysis. The synthesized compounds also demonstrate remarkable insensitivity toward visible light and UV-radiation. The combined characteristics of these compounds, such as light insensitivity, poor water solubility, high thermal stability, lack of toxicity of organic ligands, and antimicrobial activity make these silver(I) cyanoximates compounds suitable for use in biomaterial and medical devices.

Abstract: Formulations and methods are disclosed which are effective to kill or control bacteria in the nares including gram-positive bacteria strains of S. aureus that are antibiotic resistant (MRSA—methicillin-resistant Staphylococcus aureus. A preferred composition comprises one or more medium-chain alcohols (dodecanol), glycerol monoesters (glycerol monocaprylate or glycerol monolaurate), and/or benzoic acid or benzoic acid analog, in a suitable pharmaceutical carrier, preferably an ointment, along with an odorant compound, preferably eucalyptus oil. The formulations and variations of the formulation may also be used on open wounds or lesions as well as intact skin.

Abstract: The present invention relates to a personal care composition and methods of using the same, the composition including an anionic surfactant, a cationic conditioning polymer, and a silicone emulsion wherein a total content of a cyclic polysiloxane having a general formula: is present in the silicone emulsion in an amount less than 2.5 wt % based on the total weight of all polysiloxanes, R is a substituted or unsubstituted C1 to C10 alkyl or aryl, wherein m is 4 or 5, wherein the composition forms coacervate particles upon dilution with water, and wherein a percentage of the coacervate particles with a floc size of greater than about 20 micron is from about 1% to about 60% upon dilution with water.

Abstract: A composition including a Rh or Ru metalloinsertor complex specifically targets mismatch repair (MMR)-deficient cells. Selective cytotoxicity is induced in MMR-deficient cells upon uptake of the inventive metalloinsertor complexes.

Abstract: Methods and formulations for induction of local anesthetic effects employing magnetic nanoparticles conjugated to anesthetic molecules. Magnetic nanoparticle-local anesthetic conjugates may be safely injected intravenously into human and animal subjects without encountering the deleterious effects observed with traditional injections of local anesthetics. The magnetic nanoparticle-local anesthetic conjugate may be concentrated at a site of action through the application of an external magnetic field to the patient at a site where local anesthesia is desired.

Abstract: A method of achieving improved hair feel. The method comprises applying to hair a composition comprising: (a) a specific cationic guar polymer; (b) a specific cationic copolymer; (c) an anti-dandruff active; (d) a cosmetically acceptable carrier; (e) a surfactant; wherein the weight ratio of (a):(b) is from about 1000:1 to about 3.5:1; and wherein the sum of (a)+(b) is an amount of from about 0.0001% to about 0.7%, by total weight of the composition. The composition forms coacervate particles upon dilution of the composition with water and the coacervate particles have a squeeze flow viscosity of from about 1 cP to about 100 cP. The percentage of coacervate particles with a floc size of greater than about 20 micron is from about 1% to about 60% and the on-scalp deposition of the anti-dandruff active is at least about 1 microgram/cm2.

Abstract: The present disclosure relates to methods of treating a range of diseases or conditions. The methods involve administration of a superoxide dismutase mimetic.

Abstract: An ecologically compatible anti-microbial-adhesion agent is described, which is particularly suitable for use in anti-fouling paints, preferably for boats, characterized in that it comprises a compound selected from eugenol, vanillin, benzaldehyde substituted with one or two substituents selected from the groups —OH (hydroxy) and —OCH3 (methoxy), or any combination thereof. An anti-fouling paint is also described, particularly for boats, comprising the anti-microbial-adhesion agent mentioned above and other components selected from conventional biocides, solvents, resins, pigments, charges and fillings, and combinations thereof.

Abstract: The present invention relates to novel iridium and/or rhodium containing complexes for use as a cytotoxic, such as an anti-cancer agent. There is also provided a method of preparing said compounds.

Abstract: Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating natural surfaces that contain bacterial biofilm, including unexpected synergy or enhancing effects between bismuth-thiol (BT) compounds and certain antibiotics, to provide formulations including antiseptic formulations. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating certain gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating certain gram-negative bacterial infections.

Abstract: Personal care composition and methods are included with respect to a dried zinc pyrithione-polymer aggregate.

Abstract: Personal care compositions including dried zinc pyrithione are provided.

Abstract: There is provided an antifouling coating composition capable of forming an antifouling coating film which has stable coating film consumption degree on ships, underwater structures and the like and which exhibits excellent antifouling property over a long term. The antifouling coating composition includes a hydrolyzable copolymer (A) and an antifouling agent (B), wherein the hydrolyzable copolymer (A) is, e.g., a metal salt bond-containing copolymer having a component unit derived from a monomer (a21) represented by the general formula (II): CH2?C(R2)—COO-M-O—CO—C(R2)?CH2??(II) [In the formula (II), M is zinc or copper, and R2 is a hydrogen atom or a methyl group], and a component unit derived from other unsaturated monomer (a22) copolymerizable with the monomer (a21), and wherein the antifouling agent (B) includes at least medetomidine.

Abstract: Methods of enhancing skin hydration include applying a leave-on moisturizing composition comprising a zinc-containing material and/or a pyrithione material.

Abstract: A skin engaging member suitable for use in a hair removal device, said skin engaging member comprising an anti-irritation agent.

Abstract: A method of enhancing skin hydration, the method including applying a rinse-off personal care composition comprising at least one of a zinc-containing material and a pyrithione material to non-diseased skin of an individual.

Abstract: Methods are provided to enhance deposition of zinc pyrithione.

Abstract: A personal care composition comprising an anti-irritation agent such as a zinc pyrithione, a zinc salt or a combination thereof.

Abstract: The present invention relates to the use of certain osmium containing complexes such as cytotoxic agents particularly for the treatment of cancer. There is also provided novel osmium containing complexes, as well as pharmaceutical formulations comprising such complexes.

Abstract: The invention relates to a composition in the form of an emulsion that can be expanded by an aerosol dispenser, characterized in that it comprises from 15 to 20 volume % of alcohol, from 1 to 10 volume % of C3-C8 polyolen, a thickening agent, at least one non-ionic surfactant, a wetting agent, and one or more active ingredients dissolved or in suspension; the invention also relates to the medical and cosmetic applications thereof.

Abstract: Compositions and methods for treating and/or preventing conditions such as diaper rash and atopic dermatitis are disclosed. The compositions and methods are particularly useful in the treatment and prevention of diaper rash and diaper dermatitis caused by the prolonged contact of human skin with body waste. The methods employ the topical application of a trypsin-inhibiting agent to the area in need of such treatment, or the area where prevention is desired. The trypsin-inhibiting agent is preferably a divalent cation/anion pair.

Abstract: The present invention is related to surfactant-based formulations comprising the polyelectrolytes and blends of such polyelectrolytes with non-cellulosic cationic polysaccharide polymers. The surfactant-based formulations exhibit improved clarity of the resulting formulations, their improved conditioning of keratin substrates, textile substrates, and hard-surface substrates, their improved deposition of dispersed phase materials onto keratin substrates, textile substrates, and hard-surface substrates, their improved lather performance, and their improved rheology in applications such as personal care and household care products and textile applications.

Abstract: The present invention relates to uses or methods for treating proliferative diseases, in particular cancer, implementing ruthenium compounds, as well as to composition containing same.

Abstract: A method of making a stable detersive surfactant containing personal care composition comprising the steps of emulsifying a stabilizing agent in the presence of anionic surfactant to form an emulsion containing droplets having a particle size of from about 0.1 to about 10 um. These particles are then cooled to form a stabilizing premix at a rate of about 10 to about 1000 C/min to form crystals from the droplets, the crystals having a maximum dimension of about 0.1 to about 3 um. These crystals are then added to a detersive surfactant containing personal care composition to increase stability.

Abstract: The present invention relates to new rhenium compounds of formula (I) with medical utility, corresponding pharmaceutical compositions as well as medical uses thereof.

Abstract: The present invention provides a composition having an excellent controlling activity on plant disease. The composition comprising the compound represented by the formula (1) and one or more inorganic fungicidal compound selected from the group (A) shows an excellent controlling activity on a plant disease. group (A): a group consisting of fludioxonil, pencycuron, ametoctradin, chloroneb, chlorothalonil, oxine-copper, cyflufenamid, dichlofluanid, dicloran, diethofencarb, dinocap, dithianon, edifenphos, fenaminosulf, fentin, fluazinam, fluoroimide, flusulfamide, flutianil, fosetyl-Al, hydrargaphen, iprobenfos, metrafenon, milneb, penflufen, phosdiphen, phthalide, prothiocarb, pyrazophos, sedaxane, silthiofam, spiroxamine, tebufloquin, and tolyfluanid.

Abstract: Hair treatment composition comprising a zinc-based antidandruff agent, a conazole fungicide and a cationic modified guar deposition polymer.

Abstract: The present invention relates to an antimicrobial composition comprising an isothiazolin-3-one, such as 1,2-benzisothiazolin-3-one, a zinc compound selected from zinc salts, zinc oxide, zinc hydroxide or combinations thereof, a pyrithione salt or pyrithione acid, and a surfactant selected from the group consisting of (i) an anionic surfactant having a sulfate or sulfonate moiety attached to a straight or branched chain containing from about 10 to about 18 atoms at the backbone of the chain, (ii) an anionic surfactant being an alkylaryl sulfonic acid or salt thereof wherein the alkyl portion contains from about 10 to about 18 carbon atoms, and the aryl portion contains a benzyl or substituted benzyl group, and combinations thereof. This composition is particularly effective in preventing the growth of various microorganisms in mineral slurries such as aqueous calcium carbonate slurries.

Abstract: A shampoo composition that increases the deposition and retention of benefit agent containing polyacrylate microcapsules onto hair during the cleansing process. The shampoo composition is based on the combination of anionic charged polyacrylate microcapsules, cationic deposition polymers, detersive surfactant, and a carrier.

Abstract: Provided are methods of treating pain, including neuropathic pain, in human and veterinary individuals. These methods employ locally administrable pharmaceutical gallium compositions, including pharmaceutical gallium compositions suitable for administration to the skin and mucous membranes. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate or gallium nitrate, together with pharmaceutically acceptable carriers suitable for local administration, including those suitable for topical administration. The administration of such compositions provides relief from pain, itching, allodynia, hyperalgesia, and related symptoms.

Abstract: The present invention provides for the purposeful utilisation of the induction of senescence in eukaryotic cells for induction of an antigen specific immune response. Such cells can be normal cells, pre-malignant and malignant cells as well as virally or bacterially infected cells, for the generation of an immune response, preferably a cellular or humoral immune response comprising T-cells and/or B-cells, whose immune response is directed specifically against antigens from those cells in which senescence was induced and then comprises an immune response against the senescent cells itself as well as to the non-senescent counterparts harbouring the same antigens.

Abstract: The present invention provides complexes of gallium with a ligand, methods of making the complexes, methods of using the complexes and pharmaceutical gallium compositions comprising the complexes, in particular those compositions suitable for therapeutic oral administration.

Abstract: The present invention describes Photolabile Compounds methods for use of the compounds. The Photolabile Compounds have a photoreleasable ligand, which can be biologically active, and which is photoreleased from the compound upon exposure to light. In some embodiments, the Photolabile Compounds comprise a light antenna, such as a labeling molecule or an active derivative thereof. In one embodiment, the light is visible light, which is not detrimental to the viability of biological samples, such as cells and tissues, in which the released organic molecule is bioactive and can have a therapeutic effect. In another embodiment, the photoreleasable ligand can be a labeling molecule, such as a fluorescent molecule.

Abstract: The present invention includes compositions and method to improve the therapeutic index of anti-cancer agents using a novel anti-cancer agent and a modulator or potentiator thereof

Abstract: A method for topical treatment of rosacea comprising application of a formulation to the affected area is disclosed. The formulation comprises one or more iron chelators. Omadine, a bispyrithione salt, and kojic acid are the preferred iron chelators. The formulation also comprises one or more false substrates for arachidonic acid. The preferred false substrates for arachidonic acid are alpha-linoleic acid and gamma dihomo-linolenic acid. The formulation further comprises an inhibitor of stratum corneum tryptic enzyme (SCTE). A preferred stratum corneum tryptic enzyme inhibitor is zinc. The formulation also preferably includes one or more medium-chain saturated fatty acid monoester. The preferred medium-chain fatty acid monoesters are glycerol monolaurate and glycerol monocaprylate. Formulation components are solubilized in a suitable carrier base which includes emollient, humectant, antioxidant and sunscreen components. The method preferably comprises application of a leave-on formulation.

Abstract: Claimed are a compound of the general formula (I) and pharmaceutically acceptable salts thereof, where M signifies metal atoms selected independently from the group comprising Pd, Fe, Mn, Co, Ni, Cu, Zn and Mo; R1 and R2, independently of each other, signify hydrogen, amino, hydroxy, oxy, carboxy, cyano, C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C1-12alkoxy, C1-12alkylamino, C1-12alkoxycarbonyl, C1-12alkylamido, arylamido, wherein the alkylene groupings in the given substituents can in turn be substituted by one or more of the following groups: hydroxy, oxy, carboxy, amino or amido; R3-R10, independently of each other, signify hydrogen; or NHR3R4 and NHR5R6, taken together, and/or NHR7R8 and NHR9R10, taken together, are a ligand (or ligands) containing one or several donor aliphatic or aromatic atoms of nitrogen and being in cis position on the metal atoms (M).